Compare PYPD & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PYPD | SRTS |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.0M | 67.5M |
| IPO Year | 2020 | 2016 |
| Metric | PYPD | SRTS |
|---|---|---|
| Price | $4.72 | $4.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $12.00 | $8.00 |
| AVG Volume (30 Days) | ★ 74.5K | 71.4K |
| Earning Date | 02-11-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $35,609,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $3.03 |
| 52 Week High | $4.97 | $9.08 |
| Indicator | PYPD | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 75.13 | 68.77 |
| Support Level | $4.10 | $4.30 |
| Resistance Level | $4.97 | $4.64 |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 80.56 | 85.86 |
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.